It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Integrating Revvity Signals ChemELN (Electronic Lab Notebook) with our informatics ecosystem. We make every experiment findable, reproducible, and secure turning your chemistry data into a trusted resource that accelerates discovery and protects your intellectual property.
We utilize ChemELN to give you a centralized, secure digital platform for managing chemical data and intellectual property.
It serves as a complete scientific record and knowledge base for every chemistry activity in your project, enabling transparent collaboration, structured data capture, and rapid reporting. By recording experimental data in a machine-readable, patent-ready format, ChemELN accelerates knowledge transfer across DMTA cycles and integrates seamlessly with analytical, registration, and informatics systems.
Supporting Your Research
Managing the vast and complex data generated by chemical synthesis can slow discovery. ChemELN streamlines these processes by:
• Providing a centralized, searchable database for all synthetic chemistry records.
• Ensuring data integrity and traceability across multiple collaborators and sites.
• Facilitating rapid knowledge retrieval for decision-making, IP protection, and reporting.
• Enabling machine-readable data formats that integrate with analytics, automation, and AI-driven design tools.
This ensures that every reaction and dataset can be easily accessed, reused, and analysed, accelerating discovery and ensuring reproducibility.
Our Integrated Advantage
The ChemELN interfaces seamlessly with analytical data systems, compound registration, and project management tools giving:
• Patent-Ready Data Capture: Experiments are recorded in a structured, compliant format designed for rapid transposition to patent documentation.
• Data Accessibility: All records are machine-readable, supporting computational chemistry, data mining, and structure–activity relationship (SAR) exploration.
• Security & Compliance: Enterprise-grade security protects IP while enabling controlled data sharing among project partners.
• Scalable Infrastructure: Supports projects of all sizes, from small exploratory studies to multi-program collaborative pipelines using modern microservices architecture
Why Choose Sygnature Discovery
Sygnature Discovery has a proven track record of integrating data management tools into workflows to enhance efficiency and insight generation.
• Proven Expertise: Our collocated chemistry and informatics teams collaborate to maintain high-quality, audit-ready experimental records for every client project.
• Client Value: Gain transparent access to live project data, secure IP management, and accelerated delivery of documentation ready for regulatory or patent submission.
With ChemELM, every experiment is findable, reproducible, and secure, giving peace of mind while accelerating your research through collaborative science.
Hélène Asnagli, Norbert Minet, Christina Pfeiffer, Eef Hoeben, Rebecca Lane, David Laughton, Louise Birch, Geraint Jones, Andrew Novak, Andrew E Parker, Heinz Ludwig, Alain Fischer, Sylvain Latour, Philip…
Andrzej T Slominski, Tae-Kang Kim, Radomir M Slominski, Yuwei Song, Shariq Qayyum, Wojciech Placha, Zorica Janjetovic, Konrad Kleszczyński, Venkatram Atigadda, Yuhua Song, Chander Raman, Cornelis J…
Ting Qin, Sergio Ernesto Ruiz Hernandez, Jason Shiers, Matthew Crittall, Andrew Novak, Colin Sambrook Smith Abstract Within a growing drug discovery company, scientists acquire (either through in house…
As CNS drug discovery grows more complex, so does the need for smarter,…
Posters
Related Solutions
We help you design smarter compounds and make faster decisions by combining AI-powered modeling, extensive scientific expertise, and secure, collaborative data access to solve complex challenges and accelerate your drug discovery journey.
Main home page for the Protein Science and Structural Biology Department. We take time to understand your target and the ultimate aims of the project and tailor our approach accordingly.
Helping you design and optimize ternary complexes with precision, combining advanced modeling and collaborative expertise, making previously “undruggable” targets tractable.
Providing Relative Binding-Free Energy Calculation using Non-Equilibrium Switching (NES) powered by OpenEye’s Orion® platform. Delivering precise binding affinity predictions to help you rank compounds with confidence and prioritize synthesis decisions for the most promising candidates early in the discovery process.
Combining AI-driven design, bespoke ML models and LLM-powered bioinformatics with hands-on collaboration to help you discover Optimized drug candidates faster.
From binding sites to druggability, our computational chemistry and protein science teams help you find the right starting points faster, combining structural insight with cutting-edge tools to design compounds that move your project forward with confidence.
Helping you design better compounds with greater confidence. Utilizing quantum-level insights and dynamic simulations we predict affinity, guide optimization, and help you prioritize the right candidates faster.
Leveraging the properties of known active molecules to rapidly generate and optimize new compounds through ligand-driven insights, AI-powered tools, and collaborative expertise to uncover new chemical space and accelerate discovery.
All major target classes, including small-molecule modulators of enzymes, GPCRs, ion channels, and protein –protein interactions.
Small molecules, fragments, covalent inhibitors, and PROTACs, with structured data fields to support custom chemotypes.
Fully digital workflows from reaction design and synthesis logging to analytical verification and registration, ensuring each experiment is linked to the broader drug discovery data pipeline.
An error has occurred, please try again later.An error has occurred, please try again later.
You're in the right place!
Peak Proteins, NuChem Sciences, and SB Drug Discovery have now fully integrated with Sygnature Discovery.
